Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
Portfolio Pulse from Benzinga Newsdesk
The United States Court of Appeals for the Federal Circuit upheld a decision by the District Court for the District of Delaware that Slayback Pharma and Apotex's drug applications referencing Eagle Pharmaceuticals' Belrapzo (Bendamustine) did not infringe on Eagle's ‘483 patent.
January 18, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eagle Pharmaceuticals' patent claim for Belrapzo was not upheld, potentially allowing competitors Slayback Pharma and Apotex to enter the market with their own versions of the drug.
The court's decision against Eagle Pharmaceuticals' patent claim could lead to increased competition as Slayback Pharma and Apotex may proceed with their drug applications. This could potentially impact Eagle's market share and revenues for Belrapzo, likely leading to a negative short-term impact on EGRX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100